宫颈癌筛查
宫颈癌是全球女性第四常见癌症,人群筛查聚焦于高级别癌前病变和癌症风险。美国癌症协会推荐25岁起筛查、首选每5年一次HPV初筛;USPSTF 2024草案推荐30岁起每5年HPV初筛、21-29岁每3年细胞学单独筛查,65岁可终止筛查需满足特定条件。
要点
- ACS推荐25岁起筛查,首选每5年一次HPV初筛。
- USPSTF 2024草案推荐30岁起每5年HPV初筛,21-29岁每3年细胞学。
- 65岁终止筛查需无高级别CIN或宫颈癌史且60及65岁筛查充分阴性。
核心结论
- 人群筛查是无症状平均风险个体预防宫颈癌的核心,聚焦高级别癌前病变和癌症风险。
- 美国 underscreening 与社会经济差异相关。
研究设计与样本
- 本文为综述,汇总全球宫颈癌筛查策略及美国相关指南推荐,未报告系统检索范围。
主要发现
- 筛查策略包括细胞学单独、联合检测和HPV初筛。
- ACS推荐25岁起筛查,首选每5年一次HPV初筛。
- USPSTF 2024草案推荐30岁起每5年HPV初筛为首选,21-29岁每3年细胞学单独筛查。
- 细胞学单独和联合检测是可接受的筛查方法。
关键数值与推荐
- ACS:25岁起筛查,首选每5年一次HPV初筛。
- USPSTF 2024草案:30岁起每5年HPV初筛为首选,21-29岁每3年细胞学单独筛查。
- 65岁终止筛查需过去25年无高级别CIN或宫颈癌史,且60和65岁筛查充分阴性。
- 异常结果管理遵循2019 ASCCP基于风险的管理共识指南。
临床怎么用
- 对无症状平均风险个体按年龄和指南选择筛查策略,注意 underscreening 的社会经济差异。
- 异常筛查结果按2019 ASCCP基于风险共识指南管理。
局限性
- 原文未报告综述的检索范围及纳入标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globally, cervical cancer is the fourth most common cancer in women and other people with a cervix. Population-based screening, applied to asymptomatic average-risk individuals, remains the core of prevention and focuses on the risk of high-grade cervical precancers and cancers. In the United States, underscreening is associated with socioeconomic disparities. Screening strategies include cytology alone, cotesting, and primary human papillomavirus (HPV) screening. The American Cancer Society recommends initiating cervical cancer screening at 25 years of age; primary HPV testing every 5 years is the preferred method. The US Preventive Services Task Force 2024 draft recommendation endorses the use of primary HPV screening every 5 years as the preferred method beginning at 30 years of age and recommends cytology alone every 3 years in patients 21 to 29 years of age. Cytology alone and cotesting are acceptable screening methods. Conclusion of screening at 65 years of age is recommended for individuals without a history of high-grade cervical intraepithelial neoplasia or cervical cancer in the past 25 years and with adequate negative screening results at 60 and 65 years of age. Management of patients with abnormal cervical cancer screening results should follow the 2019 American Society for Colposcopy and Cervical Pathology (ASCCP) risk-based management consensus guidelines.
引用
- Wiser A, Quinlan JD. Cervical Cancer Screening. Am Fam Physician. 2026. PMID: 41839104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。